Drug Channels

SEPTEMBER 13, 2023

For 2023, specialty pharmacies—via white, brown, and clear bagging—retained a meaningful share of the distribution channels for provider-administered oncology drugs. Despite the concerted efforts of insurers such as UnitedHealthcare and Elevance Health, however, buy-and-bill remains the most common channel for these products.

Specialty Pharmacies 97

Specialty Pharmacies Pharmacy Pharmaceuticals Drugs 97

Drug Target Review

FEBRUARY 10, 2025

Over the years, Ive had the privilege of working on more than 25 different products, Bock shared. In this model, once a product is produced and delivered to the clinical pharmacy, the clinical team takes over the trial with little to no interaction with the manufacturing team.

Therapies 64

Therapies Treatment Engineering Clinical Trials 64

Drug Channels

DECEMBER 13, 2023

For 2023, specialty pharmacies—via white, brown, and clear bagging—retained a meaningful share of the distribution channels for provider-administered oncology drugs. Despite the concerted efforts of insurers such as UnitedHealthcare and Elevance Health, however, buy-and-bill remains the most common channel for these products.

Specialty Pharmacies 98

Specialty Pharmacies Pharmacy Pharmaceuticals Drugs 98

The Pharma Data

JULY 29, 2021

Food and Drug Administration approved the first interchangeable biosimilar insulin product, indicated to improve glycemic control in adults and pediatric patients with Type 1 diabetes mellitus and in adults with Type 2 diabetes mellitus. Semglee (insulin glargine-yfgn) is the first interchangeable biosimilar product approved in the U.S.

Biosimilars 52

Biosimilars Production FDA Approval FDA 52

Drug Channels

OCTOBER 23, 2023

With regulation and policy changes, specifically surrounding the DCSCA, IRA and serialization, the loss of exclusivity wave, adoption of low-WAC products affecting GTN and the rise of alternative distribution models, there has never been a more important time for industry to unite. How is health policy affecting the distribution channel?

Pharmacy 75

Pharmacy Biosimilars Marketing Production 75

Alta Sciences

DECEMBER 14, 2023

A Closer Look At Our On-Site Compounding Pharmacies shajjar Thu, 12/14/2023 - 21:30 HTML Altasciences' dedicated pharmacists bring a wealth of expertise in controlled substances and complex compounding, ensuring maximum precision and safety standards. Electronic security access to the pharmacy and video monitoring. -

Compounding Pharmacies 40

Compounding Pharmacies Pharmacy Clinical Pharmacology Clinical Supply 40

Policy Prescription

OCTOBER 3, 2023

Salant’s paper supports personal drug importation and legalizing the importation of prescription drugs for commercial use so that wholesale pharmacies, including companies like Amazon and Costco, could tap into the parallel importation markets of other countries. Third, even foreign drug prices are much higher than the cost of production.

Pharmacy 84

Pharmacy International FDA Approval Government 84

The Pharma Data

SEPTEMBER 21, 2020

Acella Pharmaceuticals is recalling two types of its thyroid medication as the drugs may be too weak to properly treat those who take them. . Photo by Adam from UK. This follows a similar recall of thyroid medications that was issued by the FDA in recent weeks.

Pharmaceuticals 52

Pharmaceuticals Pharmacy Drugs Doctors 52

Drug Channels

APRIL 19, 2021

Informa Connect’s Compliance Congress for Specialty Products. Up your compliance game at this important event serving the unique sector of Specialty Products, the 7th annual Virtual Compliance Congress for Specialty Products. June 22-24, 2021 | Virtual Event www.informaconnect.com/specialty-compliance/.

Compliance 40

Compliance Production Specialty Pharmacies Pharmacy 40

Drug Channels

SEPTEMBER 11, 2024

For 2024, payers report that specialty pharmacies—via white and clear bagging—have displaced buy-and-bill for a meaningful share of commercial covered lives utilizing provider-administered oncology drugs. Payers’ adoption of white bagging—and provider’s push back—reflect the ongoing battle for oncology margin in U.S. drug channels.

Specialty Pharmacies 52

Specialty Pharmacies Pharmacy Pharmaceuticals Drugs 52

Drug Channels

JULY 16, 2024

Last week, the Federal Trade Commission (FTC) released its interim report on pharmacy benefit managers (PBMs). The report’s unsubtle subtitle revealed how the agency views PBMs: The Powerful Middlemen Inflating Drug Costs and Squeezing Main Street Pharmacies. Pharmacies and Pharmacy Benefit Managers.

Pharmacy 52

Pharmacy Pharmaceuticals Production Drugs 52

Drug Channels

DECEMBER 10, 2024

Last week, the Federal Trade Commission (FTC) released its interim report on pharmacy benefit managers (PBMs). The reports unsubtle subtitle revealed how the agency views PBMs: The Powerful Middlemen Inflating Drug Costs and Squeezing Main Street Pharmacies. Pharmacies and Pharmacy Benefit Managers.

Pharmacy 52

Pharmacy Pharmaceuticals Drugs Production 52

Drug Channels

SEPTEMBER 21, 2020

This important event convenes key stakeholders including manufacturers, specialty pharmacies, hubs, payers, PBMs, physicians and more to explore strategies for developing and integrating hub programs and other patient-centric services to ensure product access and optimal reimbursement. Arquette, R.Ph., REGISTER TODAY.

Specialty Pharmacies 52

Specialty Pharmacies Pharmacy Pharmaceuticals Production 52

The Pharma Data

OCTOBER 19, 2020

20, 2020 /PRNewswire/ — Abarca , a pharmacy benefit manager (PBM) that is disrupting the industry with a new approach to technology and business practices released a new case study detailing a value-based agreement with Biogen Inc. It started by redefining pharmacy benefits, but this is just the beginning.

Production 40

Production Pharmacy Pharmaceutical Companies Therapies 40

DrugBank

SEPTEMBER 26, 2024

This reduction in cost does not equate to a compromise in quality or efficacy, as biosimilars undergo rigorous analytical and functional characterization to demonstrate biosimilarity to the reference product. biosimilars are often priced slightly lower than their reference products, limiting their potential for cost savings.

Biosimilars 98

Biosimilars Clinical Trials Production FDA 98

Drug Channels

JULY 20, 2021

The 340B Drug Pricing Program continues to expand far more quickly than the overall pharmaceutical market—and some channels are benefiting more than others. As you will see below, mail and specialty pharmacies’ purchases of products that are eligible for 340B discounts have grown by an incredible 56% per year since 2017.

Specialty Pharmacies 40

Specialty Pharmacies Pharmacy Marketing Pharmaceuticals 40

Policy Prescription

APRIL 1, 2022

from licensed pharmacies to American patients. This epic counterfeit drug debacle had nothing to do with the personal importation of less expensive prescription drugs or foreign online pharmacies. pharmacies and wholesalers allegedly flouting the rules. Safe Chain Pharmacy Solutions. Fake DSCSA Pedigrees.

Pharmacy 40

Pharmacy Licensing Licensing Drugs 40

Agency IQ

JANUARY 4, 2024

Now, the FDA has released guidance laying out the tests and regulatory submissions needed for the reformulation of products containing these ingredients. To help control impurities, the FDA requires all starting materials used in drug manufacturing and final pharmaceutical products to be evaluated for “identity, strength, quality and purity.”

FDA 40

FDA Production Laboratories Drugs 40

Fierce BioTech

JANUARY 19, 2024

The Cardinal Health™ Sonexus™ Access and Patient Support team will explore innovative ways to create efficiencies and improve the patient experience with AI-powered patient access backed by best-in-class pharmacy and operations.

Pharmacy 52

Pharmacy Pharmaceuticals Treatment Production 52

FDA Law Blog: Biosimilars

FEBRUARY 5, 2024

HP&M has been helping clients navigate the challenges of state licensing regulations for drugs, biologics, medical devices, OTCs, 503B outsourcing facilities, 503A pharmacies, foods, dietary supplements, cannabis, and wholesalers/distributors for many years. Keup has joined the firm to assist attorneys Karla L.

Licensing 45

Licensing Licensing Pharmacy Regulations 45

The Pharma Data

DECEMBER 19, 2020

McKesson has a long history of managing the pharmaceutical and medical supply chain in the U.S., For the ancillary supply kit production and distribution, McKesson has partnered with the Strategic National Stockpile, which is part of the Office of the Assistant Secretary for Preparedness and Response within HHS.

Government 52

Government Vaccine Pharmacy Pharmaceuticals 52

The Pharma Data

NOVEMBER 1, 2020

It is a very exciting step for our Pharmaceutical Wholesale Division and a unique chance for us to further develop innovative services to manufacturers and pharmacists in Germany.”. Together, we look forward to delivering a successful model of operations to benefit the German healthcare ecosystem of patients, pharmacies and manufacturers.”.

Pharmacy 40

Pharmacy Community Pharmacies Pharmaceuticals Licensing 40

FDA Law Blog: Biosimilars

MARCH 4, 2024

Livornese — On February 6, 2024, FDA issued a draft guidance titled Notifying FDA of a Discontinuance or Interruption in Manufacturing of Finished Products or Active Pharmaceutical Ingredients Under Section 506C of the FD&C Act.

FDA 59

FDA Production Marketing Drugs 59

Drug Target Review

AUGUST 16, 2024

I joined the pharmaceutical industry to leverage my passion and hands-on clinical experience to care for people all over the world by bringing a unique perspective to drug and device research and development. Here, I oversee the medical strategy for both existing products and those in our development pipeline, including outcomes research.

Medical Schools 111

Medical Schools Nurses Research Production 111

Drug Channels

MARCH 29, 2021

We’ve got all of the key legal and consultant perspectives on topics like 340B (including contract pharmacy arrangements), State Price Transparency, CMS current and final rules, Most Favored Nations, and more! Fresh Perspectives.

Government 52

Government Pharmacy Pharmaceuticals Production 52

Drug Channels

MARCH 29, 2021

We’ve got all of the key legal and consultant perspectives on topics like 340B (including contract pharmacy arrangements), State Price Transparency, CMS current and final rules, Most Favored Nations, and more! Fresh Perspectives.

Government 52

Government Pharmacy Pharmaceuticals Production 52

Drug Channels

JANUARY 4, 2021

Dave MacLeod, Head of Patient Services and Specialty Pharmacy Operations , Amylyx Pharmaceuticals Deepti Jaggi, Global Head of Patient Insights and Solutions , Astellas US Marina Allen, Executive Director, Patient Access and Reimbursement , Coherus BioSciences And more! Jourdan Russo, Director, Patient Services , Kyowa Kirin, Inc.

Specialty Pharmacies 52

Specialty Pharmacies Pharmacy Pharmaceuticals Drugs 52

The Pharma Data

JANUARY 13, 2021

. Psychedelic Pharmaceutical Scientist and Clinical Pharmacologist Robert Barrow Appointed as Chief Development Officer. NEW YORK , Jan.

Clinical Trials 52

Clinical Trials FDA Trials Production 52

Alta Sciences

OCTOBER 30, 2023

TOP NONCLINICAL SCIENTIFIC RESOURCES eBook : Safety Assessment for Ophthalmic Products Designing preclinical studies for ocular therapies take a lot of deliberation. Catch up on what you may have missed below! TOP MANUFACTURING AND ANALYTICAL RESOURCES The Altascientist : Issue No. Listen here.

Science 52

Science Clinical Trials Pharmacokinetics Pharmacy 52

The Pharma Data

NOVEMBER 11, 2020

McChesney is the founder and chief executive officer of Cloaked Therapeutics and Arbor Therapeutics, through which he has drawn on more than five decades of research in natural products chemistry to identify and develop novel cancer treatments. In 2009, he established Ironstone Separations Inc.,

Science 52

Science Organic Chemistry Pharmaceuticals Pharmacy 52

The Pharma Data

MARCH 26, 2021

(NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the European Medicines Agency (EMA) approved storage of COMIRNATY® at -25°C to -15°C for a total of two weeks based on data showing the stability at these temperatures in standard pharmaceutical freezers.

Vaccine 52

Vaccine Doctors Pharmacy FDA 52

The Pharma Data

DECEMBER 3, 2020

Kaseta joins Liquidia with an extensive background in corporate finance, business strategy and the commercialization of biopharma products. He also served as CFO at Aralez Pharmaceuticals Inc. Prior to UroGen, Pfreudschuh was the CFO of Sucampo Pharmaceuticals Inc., and spent 11 years at Sanofi in a variety of financial roles.

Pharmaceuticals 52

Pharmaceuticals Clinical Development Medical Schools Pharmacy 52

The Pharma Data

OCTOBER 30, 2020

Regeneron Pharmaceuticals, Inc. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to eight FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. TARRYTOWN, N.Y. ,

Hospitals 52

Hospitals Virus Production Clinical Trials 52

Drug Channels

OCTOBER 1, 2024

This week, I’m rerunning some popular posts while we put the finishing touches on DCI’s new 2024-25 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. Last week, the Federal Trade Commission (FTC) released the redacted version of administrative complaint against the three largest pharmacy benefit managers (PBMs).

Biosimilars 40

Biosimilars Pharmacy Production FDA 40

The Pharma Data

NOVEMBER 5, 2020

Forward-Looking Statements and Use of Digital Media This statement includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ materially from these forward-looking (..)

Hospitals 52

Hospitals Trials Clinical Trials Production 52

Agency IQ

MARCH 25, 2024

In proposed rule, FDA offers up a (surprisingly sparse) list of drugs that present demonstrable compounding difficulties FDA yesterday released a long-awaited proposed rule on a list of drug products that present demonstrable difficulties for compounding. The result was the addition of Section 503A to the FD&C Act.

FDA 40

FDA Pharmacy Drugs Production 40

The Pharma Data

NOVEMBER 10, 2020

He brings to this important role broad international pharmaceutical industry experience, including nearly 10 years in the US. He has deep experience in launching products, implementing new business models, expanding to new geographies and strategy development. BARCELONA, Spain , Nov.

International 52

International Pharmacy Therapies Marketing 52